RAPT Therapeutics

Yahoo Finance • 26 days ago

RAPT Therapeutics GAAP EPS of -$0.65 beats by $0.17

* RAPT Therapeutics press release [https://seekingalpha.com/pr/20296636-rapt-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights] (RAPT [https://seekingalpha.com/symbol/RAPT]): Q3 GAAP EPS of -$0.65 beats by $... Full story

Yahoo Finance • last month

RAPT Therapeutics prices equity offering at $30 per share

* RAPT Therapeutics (NASDAQ:RAPT [https://seekingalpha.com/symbol/RAPT]) priced [https://seekingalpha.com/pr/20274668-rapt-therapeutics-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of ~8.33M share... Full story

Yahoo Finance • last month

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel ther... Full story

Yahoo Finance • last month

RAPT Therapeutics announces proposed public offering

* RAPT Therapeutics (NASDAQ:RAPT [https://seekingalpha.com/symbol/RAPT]) announced [https://seekingalpha.com/pr/20274354-rapt-therapeutics-announces-proposed-public-offering-of-common-stock] on Tuesday that it has commenced an underwritt... Full story

Yahoo Finance • last month

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel ther... Full story

Yahoo Finance • last month

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for... Full story

Yahoo Finance • 2 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 2 months ago

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies fo... Full story

Yahoo Finance • 5 months ago

RAPT Therapeutics adds two new directors to board

SOUTH SAN FRANCISCO - RAPT Therapeutics, Inc. (NASDAQ:RAPT) appointed Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors, the clinical-stage biopharmaceutical company announced Monday. According to InvestingPro... Full story

Yahoo Finance • 5 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for... Full story

Yahoo Finance • 6 months ago

Rapt Therapeutics announces effective date for 1-for-8 reverse stock split

RAPT Therapeutics (RAPT) announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company’s common stock will co... Full story

Yahoo Finance • 6 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing nov... Full story

Yahoo Finance • 9 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies f... Full story

Yahoo Finance • last year

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other Worst 52-Week Low Sto... Full story

Yahoo Finance • last year

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other worst 52-week low stock... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at fourweeksFurther deepening of response in percent change i... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%)patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut of... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story